Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Emily A. Lemke DNP

Emily A. Lemke DNP profile photo picture

Assistant Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology - Medicine
Program: Hematology

Member of the Cancer Center

Publications (10)

  • Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. (Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A, Su CT, Khaki AR, Osterman CK, Glover MJ, Chiang R, Makrakis D, Talukder R, Lemke E, Olsen TA, Jain J, Jang A, Ali A, Jindal T, Chou J, Friedlander TW, Hoimes C, Basu A, Zakharia Y, Barata PC, Bilen MA, Emamekhoo H, Davis NB, Shah SA, Milowsky MI, Gupta S, Campbell MT, Grivas P, Sonpavde GP, Kilari D, Alva AS) Cancer 2022 Mar 15;128(6):1194-1205 PMID: 34882781 SCOPUS ID: 2-s2.0-85120821529 12/10/2021       1 Citation
  • Ginseng for the Management of Cancer-Related Fatigue: An Integrative Review. (Lemke EA) J Adv Pract Oncol 2021 May;12(4):406-414 PMID: 34123477 PMCID: PMC8163251 06/15/2021    
  • Early Bone Metastases are Associated with Worse Outcomes in Metastatic Urothelial Carcinoma (Nelson, Ariel A.a; f; 1 | Cronk, Robert J.a | Lemke, Emily A.a | Szabo, Anikob | Khaki, Ali R.c | Diamantopoulos, Leonidas N.c; d; 2 | Grivas, Petrosc | Nezami, Behtash Ghazie | MacLennan, Gregory T.e | Zhang, Tiang; h | Hoimes, Christopher J.f; g; h) Bladder Cancer Nelson, Ariel A. et al. ‘Early Bone Metastases Are Associated with Worse Outcomes in Metastatic Urothelial Carcinoma’. 1 Jan. 2021 : 33 – 42. 03/19/2021    
  • The Role of Metastasectomy in Urothelial Carcinoma: Where Are We in 2020? (Lemke E, Sahasrabudhe D, Guancial E, Bylow K, Johnson S, Messing E, Kilari D) Clin Genitourin Cancer 2020 08;18(4):e478-e483 PMID: 32085986 SCOPUS ID: 2-s2.0-85079745146 02/23/2020       1 Citation
  • Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. (Shah AY, Kotecha RR, Lemke EA, Chandramohan A, Chaim JL, Msaouel P, Xiao L, Gao J, Campbell MT, Zurita AJ, Wang J, Corn PG, Jonasch E, Motzer RJ, Sharma P, Voss MH, Tannir NM) Eur J Cancer 2019 06;114:67-75 PMID: 31075726 PMCID: PMC7537491 SCOPUS ID: 2-s2.0-85065059604 05/11/2019       49 Citations
  • Real-World Experience With Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Analysis. (Lemke EA, Shah AY, Campbell M, Tannir NM) J Adv Pract Oncol 2019 May-Jun;10(4):333-339 PMID: 33343982 PMCID: PMC7520741 05/01/2019    
  • Current and Future Landscape of Immune Checkpoint Inhibitors in Urothelial Cancer. (Alhalabi O, Shah AY, Lemke EA, Gao J) Oncology (Williston Park) 2019 Jan 17;33(1):11-8 PMID: 30731013 SCOPUS ID: 2-s2.0-85061248960 02/08/2019       7 Citations
  • Management of Advanced Bladder Cancer: An Update. (Lemke EA, Shah AY) J Adv Pract Oncol 2018 May-Jun;9(4):410-416 PMID: 30719393 PMCID: PMC6347090 02/06/2019    
  • Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis. (Campbell MT, Bilen MA, Shah AY, Lemke E, Jonasch E, Venkatesan AM, Altinmakas E, Duran C, Msaouel P, Tannir NM) Eur J Cancer 2018 11;104:188-194 PMID: 30380460 SCOPUS ID: 2-s2.0-85055581077 11/01/2018       33 Citations
  • Vaginal Testosterone for Management of Aromatase Inhibitor-Related Sexual Dysfunction: An Integrative Review. (Lemke EA, Madsen LT, Dains JE) Oncol Nurs Forum 2017 05 01;44(3):296-301 PMID: 28635978 SCOPUS ID: 2-s2.0-85018413340 06/22/2017       5 Citations
  • Last update: 01/11/2022